Synaptogenix, Inc. (Nasdaq: SNPX) has announced a collaboration with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). The study aims to evaluate the drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients. Cleveland Clinic will oversee the implementation of the clinical trial, which includes submitting an Investigational New Drug (IND) application to the US Food and Drug Administration and enrolling patients.
Robert Fox, MD, Vice-Chair for Research at Cleveland Clinic, expressed enthusiasm about exploring the safety and potential activity of Bryostatin-1 on cognitive impairment in MS. He emphasized that cognitive impairment is a significant unmet need in MS treatment and that this investigational drug could have a profound impact.
Dr. Alan Tuchman, CEO of Synaptogenix, stated that they are moving forward with their clinical development plans for Bryostatin-1 in MS in collaboration with Cleveland Clinic. He highlighted that none of the currently available treatments address the loss of synapses caused by MS.